The trajectory of Viagra, formerly marketed by copyright, presents a fascinating case study for investors considering the pharmaceutical sector. Although its early success and impact of billions in earnings , the exclusivity end has opened the way for alternative medications, substantially reducing earnings potential . This shift raises concerns ab